89371-37-9

Imidapril is a new ACE inhibitor launched in Japan as a once-daily therapy for hypertension. Its active metabolite has more potent inhibitory effects on all tissue ACES from spontaneously hypertensive rats (SHRs) and Wistar Kyoto rats (WKYs) than many other ACE inhibitors including enalapril and captopril. It has a very long duration of action. In strokeprone spontaneously hypertensive rats (SHRSP), imidapril is effective in stroke prevention at a considerably lower dose than enalapril. This stroke preventive effect has been suggested to be primarily by an indirect mechanism related to the amelioration of kidney dysfunction.

White Solid

Tanabe (Japan)

Angiotensin converting enzyme (ACE) inhibitor. Antihypertensive

ChEBI: Imidapril is a member of the class of imidazolidines that is (4S)-1-methyl-2-oxoimidazolidine-4-carboxylic acid in which the hydrogen of the imidazolidine nitrogen has been substituted by (1S)-1-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}ethyl group. It is the prodrug for imidaprilat, an ACE inhibitor used for the treatment of chronic heart failure. It has a role as an antihypertensive agent, an EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor and a prodrug. It is a dipeptide, a member of imidazolidines, a dicarboxylic acid monoester, a secondary amino compound, an ethyl ester and a N-acylurea.

Tanatril; Novarok